Scurvy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Scurvy Market Outlook

Thelansis’s “Scurvy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Scurvy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Scurvy Overview

Scurvy presents as a clinical syndrome stemming from an inadequate vitamin C. Within 4 to 12 weeks after discontinuing vitamin C consumption, the body's reservoir of this vitamin typically becomes depleted. Various factors can negatively impact the absorption and functions of ascorbic acid. Unlike most animals, humans cannot synthesize their vitamin C and thus depend on external sources. Vitamin C is essential for humans, while other animals don't require it from external sources. Several factors can lead to vitamin C deficiency, including alcoholism, infants relying solely on cow's milk, elderly individuals subsisting on a tea and toast diet, economically disadvantaged individuals with limited access to fruits and vegetables, smokers, those with eating disorders, individuals with Type 1 diabetes requiring higher vitamin C intake, people with gastrointestinal conditions like inflammatory bowel disease, those with iron overload leading to excessive vitamin C excretion by the kidneys, and individuals following restrictive diets or dealing with food allergies. Direct supplementation is the norm to remedy vitamin C deficiency, with recommended daily doses of up to 300 mg for children and between 500 mg to 1000 mg for adults. The differential diagnosis encompasses various skin-related purpura conditions, such as immune thrombocytopenic purpura, Henoch-Schonlein purpura, disseminated intravascular coagulation, Rocky Mountain spotted fever, meningococcemia, and hypersensitivity vasculitis.

• The prevalence of vitamin C deficiency stands at 8.4%, with higher rates observed in Europe, particularly 10% among men and 6.9% among women.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: